Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Long-Term Deferred Tax (2021 - 2022)

Actinium Pharmaceuticals (ATNM) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $89000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Long-Term Deferred Tax fell 84.16% to $89000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $89000.0, a 84.16% decrease, with the full-year FY2022 number at $89000.0, down 84.16% from a year prior.
  • Long-Term Deferred Tax was $89000.0 for Q4 2022 at Actinium Pharmaceuticals, down from $562000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $562000.0 in Q4 2021 to a low of $89000.0 in Q4 2022.